S106 • OFID 2019:6 (Suppl 2) • Poster Abstracts real BSI, respectively. Of those judged to be contaminants, 10 (20%) were positive in both bottles within a set, and thus falsely suggested true BSI. Of the 3 judged to be true BSI, 2 (66%) were positive in 1 out of 2 bottles, and thus falsely suggested contamination. 42 (84%) patients had repeat BCx drawn following the initial positive culture, and 26 (52%) were continued on IV antibiotics. Forty (80%) of the cultures were judged contaminants by the primary medical service, and 77% stopped antibiotics (20/26) when CoNS was identified.
Background. In order to target future randomized controlled trials (RCT) of treatment of methicillin-resistant S aureus bloodstream infections (MRSA BSI), it will be important to understand the drivers of antibiotic selection. We aimed to determine factors associated with switching from vancomycin to inpatient linezolid administration during the management of MRSA BSI.
Methods. This retrospective cohort included all patients admitted to Veteran Affairs hospitals from 2007 to 2014 and had received vancomycin for MRSA BSI. Patients were considered to have switched to linezolid from vancomycin if they received at least 2 consecutive days of inpatient treatment and were not on concurrent vancomycin treatment. Cox proportional hazards models were used to identify factors that were associated with switch within 14 days and 30 days. Median with interquartile range (IQR), hazard ratio (HR) and 95% confidence intervals were reported.
Results. Among 7289 patients diagnosed with MRSA BSI during their index admission, 474 (6.5%) switched to linezolid during the admission. The median inpatient duration of vancomycin treatment among all patients was 13 days (IQR: 5-34) and among patients who switched was 16 days (IQR: 6-52). The median inpatient duration of linezolid treatment was 5 days (IQR: 1-13 days). Patients who switched to linezolid were more likely to have a MRSA isolate with MIC >=2 µg/mL (6.8% vs. 4.9%), diagnosis of respiratory tract infection (36.7% vs. 32.9%), or be obese (16.5% vs. 13.6%) than those who continued on vancomycin (P < 0.10). In risk-adjustment models, presence of a respiratory tract infection diagnosis was associated with greater likelihood of being switched to linezolid within 14-and 30-days (HR=1.29, 95% CI 1.01-1.64; HR=1.32, 95% CI 1.06-1.65).
Conclusion. Less than 10% of patients initially treated with vancomycin for MRSA BSI were switched to linezolid in this real-world study. A diagnosis of respiratory tract infection was a major determinant of switching to linezolid. It is important to identify potential subsets of MRSA BSI patients so that future comparative effectiveness RCTs can be targeted to indications with clinical equipoise in real-world practice settings.
Disclosures. All authors: No reported disclosures. Results. Fifty-seven cases were included, of which 70% were males. Mean age was 51 years (± 16.8) . Eleven (19%) were in association with prosthetic valves and 6 (11%) with implantable cardiac devices (Table 1) . Fever (84%), dyspnea (46%) and heart failure were the commonest presentations. The majority of patients had preexisting valvular heart disease or intra-cardiac devices (Table 1) . Skin infections (10, 18%) were the most prevalent portals of infection, followed by venous catheters, recent valve surgery and implantable cardiac devices (Table 1) . Staphylococcus species were implicated in 19 (34%) and Streptococcaceae in 9 (16%); whereas 21 (37%) were culture-negative (Table 2) . Left-side IE (49, 86%) was predominant. Acute kidney injury (AKI) (17, 30%) and heart failure (11, 19%) were common complications. The most frequently used treatment regimens included glycopeptides or Β-lactams (Table 2) . Only 9 (16%) patients underwent surgical intervention. Fourteen (25%) patients died of any cause before hospital discharge. Logistic regression analysis identified septic shock and AKI as the only risk factors independently associated with in-hospital mortality (Table 3) .
Infective Endocarditis in
Conclusion. Skin infections are an important risk for IE in Qatar. The majority of patients with IE have preexisting cardiac conditions. Staphylococci are the commonest confirmed bacterial etiology of IE in Qatar, but nearly one-third of cases are culture-negative. Only a small proportion of patients with IE undergo surgical intervention and overall mortality is high. The findings suggest that efforts should be directed toward improving IE prevention strategies in high-risk patients, encourage early microbiological investigations and improved medical and surgical management.
